



# **Revolutionary Drug Delivery Platform**

Presentation London & Abu Dhabi

June 2010

# Forward Looking Statements

This presentation provides only an overview of a Stirling Products Limited ABN 32 077 105 429 (ASX:STI) Joint Venture Opportunity. The information may require further explanation and/or clarification. Accordingly, this information should not be relied upon independently and should be considered in conjunction with past and future public information and announcements that are made by STI. Please contact STI and/or refer to the Company's website for further information.

The views expressed in this presentation may contain information derived from publicly available sources that have not been independently verified. No representation or warranty is made as to the accuracy, completeness or reliability of the information. Any forward looking statements in this presentation have been prepared on a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside STI's control. These factors could cause actual results to differ materially from assumptions or expectations expressed or implied in this presentation. Because actual results may differ materially to assumptions made and STI's current intentions, plans, expectations and beliefs about the future, you are urged to view all forward looking statements contained in this presentation with caution.

**Nothing in this presentation should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.**

# The Extraordinary Stirling Opportunities

## 1. A Blockbuster “Re-generator”

A platform for partnering with Big Pharma to secure retention of their market share as their blockbuster drugs come off patent

## 2. A Premium Generics Opportunity

A platform for marketing generic drugs at premium prices as current blockbusters come off patent

**GLOBALY UNPRECEDENTED**


# Stirling Advanced Drug Delivery

- Stirling has a joint venture interest in a proprietary 'platform' technology for improved drug delivery via the lungs.
- Pulmonary drug delivery technologies and options are being widely pursued and developed by Big Pharmas and others, at a cost of hundreds of millions.
- The Stirling technology is proven and now in the device pre-production stage. An earlier version has achieved FDA approval
- Stirling pre-production fully operational prototypes will be available for final road testing in Q1, 2011.

# Breakthrough Drug Delivery Platform

**ONLY device in the world that offers ALL of the following:**


- Drug transport velocity - matched to natural breathing cycle
- Less deposition on drug delivery pathways
- Aerosol concentration - ~3x other ultrasonic devices
- Delivered drugs have much better & faster absorption – bioavailability due to improved particle size distribution
- Proven to require substantively LESS active drug (10-15% of oral) for the same benefit – **potentially less side-effects**
- Active drug packaged in unique single-use disposable capsules – IP protection



**TECHNOLOGY IS PROVEN, DEVELOPED, & PATENTED**


# Advanced Drug Delivery Solutions

- FDA 510K approval – predicate devices



- Low power consumption allows portability with rechargeable battery power in compact hand-held package – improving compliance with therapy
- The potential for **increased safety** can transform off-patent blockbuster drugs to exclusive Stirling 'premium' generic product

# Stirling Products Inhalation Platform Device Layout



# AN UNPRECEDENTED GLOBAL OPPORTUNITY

- Forecast **\$80-100bn decline** in pharma revenue worldwide through to 2014.
- Caused by patients switching to cheaper generic versions of current blockbuster drugs coming off patent.
- Switch to generics short-term will affect six of the world's ten best selling drugs facing patent loss in the US in the next 2-3 years.
- Despite this the US will maintain its position as the world's largest pharma market growing to circa **US\$390bn by 2014**.
- Stirling **independently** can already source most generic drugs

Data Source: Gareth Macdonald, IMS Health 21<sup>st</sup> April 2010.



# THE EASY TARGETS

**Inhalation and intra-nasal drugs had sales exceeding US\$20 billion in 2009, including:**

- **US\$7.8 billion** (2009) Seretide/Advair – GlaxoSmithKline. Patent expires in US Sept 2010 and Europe 2013 – revoked in UK.
- **US\$3.1 billion** (2008) Spiriva - Boehringer Ingelheim. US Patents begin to expire December 2012.
- **US\$2.3 billion** (2009) Symbicort - AstraZeneca. Combination patents revoked in Europe, US patents begin to expire 2011.

# Business Opportunity 1

## Major Pharmaceutical Company Partner

- US\$millions sign-on fee.
- Partner funds all ongoing development for customisation of their compounds. (and other off-patent compounds)
- Sales revenue from drug capsules - partner retains 1/3<sup>rd</sup> for manufacturing and distribution costs, 1/3<sup>rd</sup> for profit and 1/3<sup>rd</sup> is paid to the Stirling Products Joint Venture.

## Benefits

- Blockbuster status can be retained post current patent expiry.
- Control of other companies off-patent blockbusters can be assumed through the Stirling major pharma partnership.

# Business Opportunity 2

## Stirling “in-house” Product Strategy

- Stirling manufactures devices and obtains regulatory approvals.
- Stirling sources generic versions of off-patent blockbusters from our generics partner – CIPLA (India).
- Stirling manufactures ‘safer’ generic drugs in patented “key locked” capsules.
- Stirling markets unique products globally at **premium prices**.

## Benefits

- Stirling is sole supplier of safer “unique delivery” generic drugs.
- Premium product at premium margins.
- Parallel route to market if no Big Pharma deal.



# **A TRULY UNPRECEDENTED GLOBAL OPPORTUNITY**

Thank you

Please visit: [stirlingproducts.net](http://stirlingproducts.net)